Allosteric Modulators of the CB1 Cannabinoid Receptor: A Structural Update Review

Abstract

In 2005, the first evidence of an allosteric binding site at the CB₁R was provided by the identification of three indoles of the company Organon that were allosteric enhancers of agonist binding affinity and, functionally, allosteric inhibitors of agonist activity. Since then, structure-activity relationships of indoles as CB₁R modulators have been reported. Targeting the allosteric site on CB₁R, new families structurally based on urea and on 3-phenyltropane analogs of cocaine have been discovered as CB₁R-negative allosteric modulators (NAMs), respectively, by Prosidion and by the Research Triangle Park. Endogenous allosteric ligands of different nature have been identified more recently. Thus, the therapeutic neuroprotection application of lipoxin A4, an arachidonic acid derivative, as an allosteric enhancer of CB₁R activity has been confirmed in vivo. It was also the case of the steroid hormone, pregnenolone, whose negative allosteric effects on Δ⁹-tetrahydrocannabinol (Δ⁹-THC) were reproduced in vivo in a behavioral tetrad model and in food intake and memory impairment assays. Curiously, the peroxisome proliferator-activated receptor-γ agonist fenofibrate or polypeptides such as pepcan-12 have been shown to act on the endocannabinoid system through CB₁R allosteric modulation. The mechanistic bases of the effects of the phytocannabinoid cannabidiol (CBD) are still not fully explained. However, there is evidence that CBD behaves as an NAM of Δ⁹-THC- and 2-AG. Allosteric modulation at CB₁R offers new opportunities for therapeutic applications. Therefore, further understanding of the chemical features required for allosteric modulation as well as their orthosteric probe dependence may broaden novel approaches for fine-tuning the signaling pathways of the CB₁R.

Keywords: CB1R; synthetic cannabinoids.

FIG. 1.

Structure of indoles Org27569 (pharmacological profile in Table 1), Org29647, and Org27759.

FIG. 2.

Indole derivatives as CB₁R allosteric modulators: 1, 2, 3, ABD1027, PAM1 (GAT211), and ZCZ011 (pharmacological profile in Table 1). *Race MIC mixture.

FIG. 3.

PSNCBAM-1 and its analogs as CB₁R allosteric modulators: GAT358 and 4 (pharmacological profile in Table 1).

FIG. 4.

Endogenous CB₁R allosteric modulators: lipoxin A4, pregnenolone, and pepcan-12 (pharmacological profile in Table 1).

FIG. 5.

Miscellaneous CB₁R allosteric modulators: RTI370, RTI371, JHW007, cannabidiol (CBD), and fenofibrate (pharmacological profile in Table 1).